Program
romiplostim
Also written as “Romiplostim”, “AMG 531” and “GNR-069”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Anemia, Aplastic · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Purpura, Thrombocytopenic, led by 5 companies.
Drug pageRomiplostim: every studyMany companies study it; this page follows only the 38 they lead. All 90 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 252 open or running | phase 4since May 21, 2009 | Jan 27, 2005 | Sep 14, 2029phase 3 · NCT07700238 |
| Kyowa Kirinits history only | 80 open or running | phase 3since Feb 22, 2007 | Mar 20, 2006 | none ahead |
| AO GENERIUMits history only | 20 open or running | phase 3since Jan 21, 2022 | Jan 21, 2022 | none ahead |
| Geropharmits history only | 21 open or running | phase 3since Jul 4, 2024 | Dec 7, 2022 | Mar 31, 2028phase 3 · NCT06497036 |
| Qilu Pharmaceuticalits history only | 11 open or running | phase 3since Dec 23, 2025 | Dec 23, 2025 | Oct 2029phase 3 · NCT07345000 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amgen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Jan 27, 2005.
- Jan 4, 2007Phase 2 study in Myelodysplastic SyndromesNCT00418665 · 39 enrolled
- May 10, 2007No phase study in Myelodysplastic SyndromesNCT00472290 · 72 enrolled
- Jul 26, 2007Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT00508820 · 407 enrolled
- Aug 9, 2007Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT00515203 · 22 enrolled
- Jan 31, 2008Phase 2 study in Myelodysplastic SyndromesNCT00614523 · 250 enrolled
- May 21, 2009Phase 4 study in ThrombocytopeniaNCT00907478 · 169 enrolled
- Dec 17, 2009Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT01071954 · 66 enrolled · United States, Australia, Canada and more
- Jun 10, 2010Phase 2 study in Purpura, Thrombocytopenic, IdiopathicNCT01143038 · 75 enrolled · United States, Australia, Czechia and more
- Sep 29, 2011Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT01444417 · 62 enrolled · United States, Australia, Canada
- Oct 1, 2014Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT02279173 · 203 enrolled · United States, Australia, Belgium and more
- Oct 12, 20172 phase 3 studiesNCT03362177, NCT03343847
- Apr 24, 2019Phase 3 study in Carcinoma, Non-Small-Cell LungNCT03937154 · 145 enrolled · United States, Argentina, Brazil and more
- Apr 5, 2022Phase 2 study in Anemia, AplasticNCT05323617
- Jul 7, 2026Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07700238 · 126 planned · United States, Germany, Hungary and more
Ahead
- Sep 14, 2029Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT07700238
TargetBeta
“Thrombopoietin receptor agonist”ChEMBL 37, by rule
Other programs on MPL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eltrombopagrule | GlaxoSmithKline | phase 4 | 49 |
| avatrombopagrule | Eisai | phase 4 | 25 |
| hetrombopag olaminerule | Jiangsu HengRui Medicine | phase 3 | 15 |
Studies
All 25 Amgen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07700238Purpura, Thrombocytopenic, Idiopathic · United States, Germany, Hungary and more | 3 | Recruiting | Sep 14, 2029 | 126 |
| NCT05323617Anemia, Aplastic | 2 | Withdrawn | Feb 25, 2025 | 0 |
| NCT03937154Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Mar 10, 2026 | 145 |
| NCT03362177Gastrointestinal Neoplasms · United States, Argentina, Austria and more | 3 | Completed | Jan 25, 2024 | 165 |
| NCT03343847Chemotherapy-induced Thrombocytopenia | 3 | Withdrawn | Jul 17, 2021 | 0 |
| NCT02279173Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Belgium and more | 3 | Completed | Aug 30, 2018 | 203 |
| NCT01444417Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Canada | 3 | Completed | Feb 2015 | 62 |
| NCT01143038Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Czechia and more | 2 | Completed | Sep 20, 2013 | 75 |
| NCT01071954Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Canada and more | 3 | Completed | Jan 12, 2017 | 66 |
| NCT00907478Thrombocytopenia | 4 | Completed | Jan 9, 2014 | 169 |
| NCT00614523Myelodysplastic Syndromes | 2 | Completed | Mar 31, 2011 | 250 |
| NCT00515203Purpura, Thrombocytopenic, Idiopathic | 2 | Completed | Mar 2009 | 22 |
| NCT00508820Purpura, Thrombocytopenic, Idiopathic | 3 | Completed | Jan 1, 2011 | 407 |
| NCT00472290Myelodysplastic Syndromes | – | Completed | Jul 18, 2011 | 72 |
| NCT00418665Myelodysplastic Syndromes | 2 | Completed | Mar 2009 | 39 |
| NCT00415532Purpura, Thrombocytopenic, Idiopathic | 3 | Completed | Nov 7, 2008 | 234 |
| NCT00413283Lung Neoplasms · United States, Austria, Canada and more | 2 | Completed | Dec 2008 | 63 |
| NCT00321711Myelodysplastic Syndromes | 2 | Completed | Oct 19, 2009 | 69 |
| NCT00303472Thrombocytopenia | 2 | Completed | May 2008 | 72 |
| NCT00283439Hodgkin Disease | 2 | Completed | May 2008 | 39 |
| NCT00117143Purpura, Thrombocytopenic | 2 | Completed | Jul 19, 2004 | 16 |
| NCT00116688Thrombocytopenia | 3 | Completed | Jan 2010 | 313 |
| NCT00111475Purpura, Thrombocytopenic, Idiopathic | 2 | Completed | Jun 17, 2004 | 45 |
| NCT00102336Thrombocytopenia | 3 | Completed | Dec 1, 2006 | 62 |
| NCT00102323Thrombocytopenia | 3 | Completed | Sep 1, 2006 | 63 |
How it is read
Names in the registry
- “Romiplostim”, 22 entries
- “AMG 531”, 6 entries
- “GNR-069”, 2 entries
- “Romiplostim N01”, 1 entry
- “GP404141”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 18 studies
- Anemia, Aplastic, 6 studies
- Myelodysplastic Syndromes, 4 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Purpura, Thrombocytopenic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.